- Home
- ADT vs STVN Comparison
ADT vs STVN Comparison
Compare ADT & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADT
- STVN
- Stock Information
- Founded
- ADT 1874
- STVN 1949
- Country
- ADT United States
- STVN Italy
- Employees
- ADT N/A
- STVN N/A
- Industry
- ADT Diversified Commercial Services
- STVN Containers/Packaging
- Sector
- ADT Consumer Discretionary
- STVN Consumer Discretionary
- Exchange
- ADT Nasdaq
- STVN Nasdaq
- Market Cap
- ADT 6.8B
- STVN 6.6B
- IPO Year
- ADT 2018
- STVN 2021
- Fundamental
- Price
- ADT $8.31
- STVN $22.14
- Analyst Decision
- ADT Buy
- STVN Buy
- Analyst Count
- ADT 4
- STVN 6
- Target Price
- ADT $9.05
- STVN $25.08
- AVG Volume (30 Days)
- ADT 19.8M
- STVN 326.1K
- Earning Date
- ADT 04-24-2025
- STVN 05-08-2025
- Dividend Yield
- ADT 2.64%
- STVN 0.27%
- EPS Growth
- ADT N/A
- STVN N/A
- EPS
- ADT 0.59
- STVN 0.50
- Revenue
- ADT $4,976,265,000.00
- STVN $1,215,562,040.00
- Revenue This Year
- ADT $5.89
- STVN $8.42
- Revenue Next Year
- ADT $4.28
- STVN $10.44
- P/E Ratio
- ADT $12.98
- STVN $44.76
- Revenue Growth
- ADT 5.65
- STVN 3.81
- 52 Week Low
- ADT $6.53
- STVN $16.56
- 52 Week High
- ADT $8.71
- STVN $25.75
- Technical
- Relative Strength Index (RSI)
- ADT 53.04
- STVN 46.39
- Support Level
- ADT $8.20
- STVN $21.97
- Resistance Level
- ADT $8.33
- STVN $24.43
- Average True Range (ATR)
- ADT 0.17
- STVN 1.28
- MACD
- ADT -0.03
- STVN -0.21
- Stochastic Oscillator
- ADT 40.60
- STVN 7.67
About ADT ADT Inc.
ADT Inc is a provider of security, interactive, and smart home solutions serving consumer and small business customers in the United States (U.S.). The Company conducts business under the ADT brand name. The company segments include Consumer and Small Business (CSB).
About STVN Stevanato Group S.p.A.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.